(Q42038599)

15 October 2017

title

Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2. (English)

1 reference

15 October 2017

1 reference

hepatocellular carcinoma

1 reference

T Ishikawa

1

1 reference

15 October 2017

M Imawari

2

1 reference

15 October 2017

T Moriyama

3

1 reference

15 October 2017

S Ohnishi

4

1 reference

15 October 2017

N Matsuhashi

5

1 reference

15 October 2017

G Suzuki

6

1 reference

15 October 2017

F Takaku

7

1 reference

15 October 2017

publication date

1 January 1988

1 reference

Journal of Cancer Research and Clinical Oncology

15 October 2017

published in

1 reference

15 October 2017

volume

114

1 reference

15 October 2017

issue

3

1 reference

15 October 2017

page(s)

283-290

1 reference

Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver

15 October 2017

cites work

1 reference

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo

1 reference

12 December 2020

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

12 December 2020

Systemic administration of recombinant human interleukin-2 in mice

1 reference

12 December 2020

Adoptive immunotherapy of cancer: accomplishments and prospects

1 reference

12 December 2020

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2

1 reference

12 December 2020

Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

Lysis of human solid tumor cells by lymphokine-activated natural killer cells

1 reference

12 December 2020

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor

1 reference

12 December 2020

The In Vitro Generation of Effector Lymphocytes and Their Employment in Tumor Immunotherapy

1 reference

12 December 2020

Establishment of a continuously growing cell line from primary carcinoma of the liver

1 reference

12 December 2020

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma

1 reference

12 December 2020

The fate of interleukin-2 after in vivo administration

1 reference

12 December 2020

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1 reference

12 December 2020

Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00405835

1 reference

15 October 2017

1 reference